Identification of novel targets for immunotherapies in subsets of patients with diffuse large B‐cell lymphoma (DLBCL)

Identification of novel targets for immunotherapies in subsets of patients with diffuse large B‐cell lymphoma (DLBCL)

Personalized treatment options for subsets of patients with DLBCL are beginning to emerge. Caracciolo et al. explore UMG1, an epitope of CD43 as a potential target for certain patients with DLBCL, and demonstrate promising preclinical activity of an Anti‐UMG1‐antibody. Commentary on: Caracciolo et a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of haematology 2024-02, Vol.204 (2), p.389-390
Hauptverfasser: Heini, Alexander D., Bacher, Ulrike, Pabst, Thomas
Format: Artikel
Sprache:eng
Schlagworte:
bispecific T‐cell engager
CD43 antigen
Cytotoxicity
DLBCL
Epitopes
Humans
Immunotherapy
Lymphoma
Lymphoma, Large B-Cell, Diffuse - pathology
personalized medicine
T-Lymphocytes
UMG1
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Personalized treatment options for subsets of patients with DLBCL are beginning to emerge. Caracciolo et al. explore UMG1, an epitope of CD43 as a potential target for certain patients with DLBCL, and demonstrate promising preclinical activity of an Anti‐UMG1‐antibody. Commentary on: Caracciolo et al. UMG1/CD3ε‐bispecific T‐cell engager (BTCE) redirects T‐cell cytotoxicity against diffuse large B‐cell lymphoma (DLBCL). Br J Haematol 2024;204:555‐560.
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.19195